Cargando…

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters

PURPOSE: The anticoagulation response to vitamin K antagonists is characterised by high inter-individual variability. The impact of single nucleotide polymorphisms (SNPs) in several genes of enzymes involved in the vitamin K cycle on phenprocoumon dose variability and phenprocoumon plasma concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geisen, Christof, Luxembourg, Beate, Watzka, Matthias, Toennes, Stefan W., Sittinger, Katja, Marinova, Milka, von Ahsen, Nicolas, Lindhoff-Last, Edelgard, Seifried, Erhard, Oldenburg, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Pharmacogenetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291838/ https://www.ncbi.nlm.nih.gov/pubmed/21110013 http://dx.doi.org/10.1007/s00228-010-0950-y

Ejemplares similares

Drug interaction: Omeprazole and Phenprocoumon
por: Enderle, Christa, et al.
Publicado: (2001)

The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
por: Wattanachai, Nitsupa, et al.
Publicado: (2017)

Phenprocoumon based anticoagulation is an underestimated factor in the pathogenesis of calciphylaxis
por: Russ, Philipp, et al.
Publicado: (2019)

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
por: de Wildt, Saskia N., et al.
Publicado: (2011)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus
por: Kurzawski, Mateusz, et al.
Publicado: (2012)

Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac: A case report
por: Pfeiffer, Hella, et al.
Publicado: (2016)

The effect of stopping phenprocoumon 5 days preoperatively: A retrospective study
por: Knol, Silke, et al.
Publicado: (2018)

Thrombosis of A Prosthetic Mitral Valve After Withdrawal of Phenprocoumon Therapy
por: Wilke, Andreas, et al.
Publicado: (2011)

The influence of excessive consumption of liquorice on phenprocoumon (Marcumar®): a case report
por: Roemer, Hermann Casper, et al.
Publicado: (2021)

Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation
por: Gjermeni, Diona, et al.
Publicado: (2023)

Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
por: Lindhoff-Last, Edelgard, et al.
Publicado: (2022)

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
por: Just, Katja Susanne, et al.
Publicado: (2017)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose–corrected trough concentration in the early period after liver transplantation
por: Wu, Yi, et al.
Publicado: (2021)

Explaining variability in ciclosporin exposure in adult kidney transplant recipients
por: Press, Rogier R., et al.
Publicado: (2010)

Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
por: Dziedziejko, Violetta, et al.
Publicado: (2011)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study
por: Andreassen, Trine Naalsund, et al.
Publicado: (2011)

Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography
por: Banaś, Anna, et al.
Publicado: (2011)

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
por: Gawrońska-Szklarz, Barbara, et al.
Publicado: (2012)

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
por: Azuma, Junichi, et al.
Publicado: (2012)

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
por: Hamberg, Anna-Karin, et al.
Publicado: (2013)

Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink
por: O'Meara, Helen, et al.
Publicado: (2014)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan
por: Shimazawa, R, et al.
Publicado: (2014)

Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies
por: Trompet, S., et al.
Publicado: (2015)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA
por: Vizeli, Patrick, et al.
Publicado: (2017)

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
por: Aklillu, Eleni, et al.
Publicado: (2018)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis
por: Łączna, Małgorzata, et al.
Publicado: (2021)

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis
por: Liu, Mengyuan, et al.
Publicado: (2020)

Man vs. machine: comparison of pharmacogenetic expert counselling with a clinical medication support system in a study with 200 genotyped patients
por: Preissner, Sally H., et al.
Publicado: (2021)

Ketoprofen/phenprocoumon: Coagulation disorders, elevation in international normalised ratio and lack of efficacy: case report
Publicado: (2022)

Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study
por: van Miert, Jasper H. A., et al.
Publicado: (2020)

Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy
por: Mülling, Nils, et al.
Publicado: (2021)

Resolution of left atrial appendage thrombi: No difference between phenprocoumon and non‐vitamin K‐dependent oral antagonists
por: Biller, Katharina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j7h8vah2h98io5s6u2dv6i4lvp